Plant Name: Piliostigma thonningii
Collective Molecular Activities at 10μM Activity Cutoff
List of Human Proteins Collectively Targeted by the Plant
Click Gene ID to Access Activity Profile of Individual Target
| FFAR1; FFAR4; | |
| FAAH; TERT; HPGD; CBR1; AKR1B1; HSD17B10; ALOX15; | |
| CDK6; | |
| CA2; CA12; CA1; CA9; CA7; CA4; | |
| PPARA; PPARD; PPARG; | |
| HIF1A; TP53; | |
| ABCG2; | |
| LMNA; NPC1; FABP3; FABP5; MAPT; | |
| XDH; |
List of Human Cytochrome P450 Enzymes Affected by the Plant
Click Gene ID to Access Activity Profile of Individual Enzyme
Detailed Information of Human Protein Targets
| Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
|---|---|---|---|---|
| ATP-binding cassette | ABCG2 | ATP-binding cassette sub-family G member 2 | Q9UNQ0 | CHEMBL5393 |
| Cytochrome P450 family 1 | CYP1A2 | Cytochrome P450 1A2 | P05177 | CHEMBL3356 |
| Cytochrome P450 family 1 | CYP1B1 | Cytochrome P450 1B1 | Q16678 | CHEMBL4878 |
| Cytochrome P450 family 1 | CYP1A1 | Cytochrome P450 1A1 | P04798 | CHEMBL2231 |
| Cytochrome P450 family 19 | CYP19A1 | Cytochrome P450 19A1 | P11511 | CHEMBL1978 |
| Cytochrome P450 family 2 | CYP2C19 | Cytochrome P450 2C19 | P33261 | CHEMBL3622 |
| Cytochrome P450 family 2 | CYP2C9 | Cytochrome P450 2C9 | P11712 | CHEMBL3397 |
| Cytochrome P450 family 3 | CYP3A4 | Cytochrome P450 3A4 | P08684 | CHEMBL340 |
| Enzyme_unclassified | FAAH | Anandamide amidohydrolase | O00519 | CHEMBL2243 |
| Enzyme_unclassified | TERT | Telomerase reverse transcriptase | O14746 | CHEMBL2916 |
| Enzyme_unclassified | HPGD | 15-hydroxyprostaglandin dehydrogenase [NAD+] | P15428 | CHEMBL1293255 |
| Enzyme_unclassified | CBR1 | Carbonyl reductase [NADPH] 1 | P16152 | CHEMBL5586 |
| Enzyme_unclassified | AKR1B1 | Aldose reductase | P15121 | CHEMBL1900 |
| Enzyme_unclassified | HSD17B10 | Endoplasmic reticulum-associated amyloid beta-peptide-binding protein | Q99714 | CHEMBL4159 |
| Enzyme_unclassified | ALOX15 | Arachidonate 15-lipoxygenase | P16050 | CHEMBL2903 |
| Lyase | CA2 | Carbonic anhydrase II | P00918 | CHEMBL205 |
| Lyase | CA12 | Carbonic anhydrase XII | O43570 | CHEMBL3242 |
| Lyase | CA1 | Carbonic anhydrase I | P00915 | CHEMBL261 |
| Lyase | CA9 | Carbonic anhydrase IX | Q16790 | CHEMBL3594 |
| Lyase | CA7 | Carbonic anhydrase VII | P43166 | CHEMBL2326 |
| Lyase | CA4 | Carbonic anhydrase IV | P22748 | CHEMBL3729 |
| Nuclear hormone receptor subfamily 1 group C | PPARA | Peroxisome proliferator-activated receptor alpha | Q07869 | CHEMBL239 |
| Nuclear hormone receptor subfamily 1 group C | PPARD | Peroxisome proliferator-activated receptor delta | Q03181 | CHEMBL3979 |
| Nuclear hormone receptor subfamily 1 group C | PPARG | Peroxisome proliferator-activated receptor gamma | P37231 | CHEMBL235 |
| Oxidoreductase | XDH | Xanthine dehydrogenase | P47989 | CHEMBL1929 |
| Protein Kinase | CDK6 | Cyclin-dependent kinase 6 | Q00534 | CHEMBL2508 |
| Small molecule receptor (family A GPCR) | FFAR1 | Free fatty acid receptor 1 | O14842 | CHEMBL4422 |
| Small molecule receptor (family A GPCR) | FFAR4 | G-protein coupled receptor 120 | Q5NUL3 | CHEMBL5339 |
| Transcription Factor | HIF1A | Hypoxia-inducible factor 1 alpha | Q16665 | CHEMBL4261 |
| Transcription Factor | TP53 | Cellular tumor antigen p53 | P04637 | CHEMBL4096 |
| Unclassified | LMNA | Prelamin-A/C | P02545 | CHEMBL1293235 |
| Unclassified | NPC1 | Niemann-Pick C1 protein | O15118 | CHEMBL1293277 |
| Unclassified | FABP3 | Fatty acid binding protein muscle | P05413 | CHEMBL3344 |
| Unclassified | FABP5 | Fatty acid binding protein epidermal | Q01469 | CHEMBL3674 |
| Unclassified | MAPT | Microtubule-associated protein tau | P10636 | CHEMBL1293224 |
Enrichment of Gene Ontology of Target Proteins (Activity≤10μM)
Detailed Information of Enriched Gene Ontolgy
| GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|
| MF | GO:0003824; catalytic activity | GO:0004089; carbonate dehydratase activity | 1.114E-13 | 3.032E-10 | CA1, CA12, CA2, CA4, CA7, CA9 |
| MF | GO:0005488; binding | GO:0019825; oxygen binding | 1.462E-12 | 2.653E-09 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C9, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0097267; omega-hydroxylase P450 pathway | 3.629E-12 | 5.645E-09 | CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C9 |
| MF | GO:0005488; binding | GO:0005506; iron ion binding | 8.595E-12 | 1.101E-08 | ALOX15, CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C9, CYP3A4, XDH |
| BP | GO:0008152; metabolic process | GO:0006730; one-carbon metabolic process | 4.220E-11 | 4.375E-08 | CA1, CA12, CA2, CA4, CA7, CA9 |
| BP | GO:0008152; metabolic process | GO:0016098; monoterpenoid metabolic process | 1.351E-10 | 1.279E-07 | CYP1A2, CYP2C19, CYP2C9, CYP3A4 |
| BP | GO:0051179; localization | GO:0015701; bicarbonate transport | 1.514E-10 | 1.373E-07 | CA1, CA12, CA2, CA4, CA7, CA9 |
| BP | GO:0008152; metabolic process | GO:0019373; epoxygenase P450 pathway | 2.889E-10 | 2.330E-07 | CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C9 |
| MF | GO:0003824; catalytic activity | GO:0070330; aromatase activity | 4.765E-10 | 3.578E-07 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP3A4 |
| MF | GO:0005488; binding | GO:0020037; heme binding | 2.741E-09 | 1.530E-06 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C9, CYP3A4 |
| BP | GO:0050896; response to stimulus | GO:0042738; exogenous drug catabolic process | 4.424E-09 | 2.240E-06 | CYP1A2, CYP2C19, CYP2C9, CYP3A4 |
| MF | GO:0003824; catalytic activity | GO:0034875; caffeine oxidase activity | 2.177E-08 | 9.675E-06 | CYP1A2, CYP2C9, CYP3A4 |
| BP | GO:0050896; response to stimulus | GO:0009725; response to hormone | 1.717E-07 | 6.030E-05 | AKR1B1, CA2, CA9, CYP1A2, FABP3, FFAR4, HPGD, NPC1, PPARA, PPARG |
| BP | GO:0009987; cellular process | GO:0071456; cellular response to hypoxia | 1.172E-06 | 3.073E-04 | HIF1A, LMNA, PPARD, TERT, TP53 |
| BP | GO:0008152; metabolic process | GO:0070989; oxidative demethylation | 1.186E-06 | 3.073E-04 | CYP1A2, CYP2C9, CYP3A4 |
| MF | GO:0005488; binding | GO:0008270; zinc ion binding | 1.163E-06 | 3.073E-04 | CA1, CA12, CA2, CA4, CA7, CA9, PPARA, PPARD, PPARG, TP53 |
| BP | GO:0008152; metabolic process | GO:0034754; cellular hormone metabolic process | 1.414E-06 | 3.622E-04 | AKR1B1, CYP19A1, CYP1A1, CYP1B1, CYP3A4 |
| BP | GO:0050896; response to stimulus | GO:0050728; negative regulation of inflammatory response | 1.929E-06 | 4.828E-04 | CYP19A1, FFAR4, PPARA, PPARD, PPARG |
| BP | GO:0050896; response to stimulus | GO:0033189; response to vitamin A | 3.642E-06 | 8.348E-04 | CYP1A1, PPARD, PPARG |
| BP | GO:0050896; response to stimulus | GO:0014070; response to organic cyclic compound | 4.225E-06 | 9.387E-04 | CA2, CA9, CYP1A1, CYP1A2, CYP1B1, HPGD, NPC1, PPARG, TP53 |
| BP | GO:0050896; response to stimulus | GO:0080134; regulation of response to stress | 5.618E-06 | 1.188E-03 | CDK6, CYP19A1, FFAR4, HIF1A, LMNA, MAPT, PPARA, PPARD, PPARG, TERT, TP53, XDH |
| BP | GO:0009987; cellular process | GO:0071310; cellular response to organic substance | 6.217E-06 | 1.289E-03 | AKR1B1, ALOX15, CDK6, CYP1A1, CYP1B1, FFAR4, HIF1A, NPC1, PPARD, PPARG, TP53 |
| BP | GO:0051179; localization | GO:0015908; fatty acid transport | 6.383E-06 | 1.311E-03 | FABP3, PPARA, PPARD, PPARG |
| BP | GO:0050896; response to stimulus | GO:0055093; response to hyperoxia | 7.088E-06 | 1.429E-03 | CYP1A1, PPARG, TP53 |
| BP | GO:0009987; cellular process | GO:0042981; regulation of apoptotic process | 7.568E-06 | 1.512E-03 | AKR1B1, CYP1B1, FFAR4, HIF1A, HPGD, LMNA, MAPT, PPARD, PPARG, TERT, TP53, XDH |
| BP | GO:0008152; metabolic process | GO:1902895; positive regulation of pri-miRNA transcription from RNA polymerase II promoter | 8.197E-06 | 1.608E-03 | HIF1A, TERT, TP53 |
| CC | GO:0044464; cell part | GO:0044444; cytoplasmic part | 9.159E-06 | 1.734E-03 | ABCG2, AKR1B1, ALOX15, CA1, CA2, CA4, CA7, CBR1, CDK6, CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C9, CYP3A4, FAAH, FABP3, FABP5, FFAR4, HIF1A, HPGD, HSD17B10, LMNA, MAPT, NPC1, PPARG, TERT, TP53, XDH |
| BP | GO:0008152; metabolic process | GO:0009404; toxin metabolic process | 9.415E-06 | 1.764E-03 | CYP1A1, CYP1A2, CYP1B1 |
| BP | GO:0009987; cellular process | GO:0032849; positive regulation of cellular pH reduction | 9.558E-06 | 1.764E-03 | CA2, CA7 |
| MF | GO:0003824; catalytic activity | GO:0070576; vitamin D 24-hydroxylase activity | 9.558E-06 | 1.764E-03 | CYP1A1, CYP3A4 |
| BP | GO:0050896; response to stimulus | GO:0035902; response to immobilization stress | 1.075E-05 | 1.918E-03 | CYP1A1, CYP1A2, PPARG |
| BP | GO:0050896; response to stimulus | GO:0042060; wound healing | 1.113E-05 | 1.970E-03 | ALOX15, PPARA, PPARD, TP53 |
| BP | GO:0008152; metabolic process | GO:0009299; mRNA transcription | 1.220E-05 | 2.125E-03 | HIF1A, PPARD, TP53 |
| BP | GO:0008152; metabolic process | GO:2000377; regulation of reactive oxygen species metabolic process | 1.268E-05 | 2.192E-03 | CYP1B1, HIF1A, MAPT, TP53, XDH |
| BP | GO:0008152; metabolic process | GO:0006706; steroid catabolic process | 1.377E-05 | 2.343E-03 | CYP19A1, CYP1A2, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0044242; cellular lipid catabolic process | 1.420E-05 | 2.393E-03 | CYP1B1, FAAH, FABP3, FABP5, PPARD |
| BP | GO:0008152; metabolic process | GO:0018894; dibenzo-p-dioxin metabolic process | 1.909E-05 | 3.035E-03 | CYP1A1, CYP1A2 |
| BP | GO:0051179; localization | GO:0010891; negative regulation of sequestering of triglyceride | 3.179E-05 | 4.741E-03 | PPARA, PPARG |
| MF | GO:0003824; catalytic activity | GO:0101020; estrogen 16-alpha-hydroxylase activity | 3.179E-05 | 4.741E-03 | CYP1A1, CYP3A4 |
| BP | GO:0050896; response to stimulus | GO:1901652; response to peptide | 3.475E-05 | 5.147E-03 | AKR1B1, FABP3, FFAR4, PPARA, PPARG, TP53 |
| BP | GO:0009987; cellular process | GO:0060548; negative regulation of cell death | 3.716E-05 | 5.468E-03 | AKR1B1, FFAR4, HIF1A, LMNA, NPC1, PPARA, PPARD, TERT, TP53 |
| MF | GO:0005488; binding | GO:0001221; transcription cofactor binding | 4.059E-05 | 5.931E-03 | PPARA, TERT, TP53 |
| MF | GO:0003824; catalytic activity | GO:0009055; electron transfer activity | 4.234E-05 | 6.066E-03 | AKR1B1, CYP19A1, CYP1A2, XDH |
| BP | GO:0051179; localization | GO:0010887; negative regulation of cholesterol storage | 4.763E-05 | 6.564E-03 | PPARA, PPARG |
| BP | GO:0008152; metabolic process | GO:0010871; negative regulation of receptor biosynthetic process | 4.763E-05 | 6.564E-03 | PPARA, PPARG |
| BP | GO:0008152; metabolic process | GO:0002933; lipid hydroxylation | 4.763E-05 | 6.564E-03 | CYP1A1, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:2001300; lipoxin metabolic process | 4.763E-05 | 6.564E-03 | ALOX15, HPGD |
| MF | GO:0005488; binding | GO:0050543; icosatetraenoic acid binding | 4.763E-05 | 6.564E-03 | FABP3, PPARG |
| MF | GO:0003824; catalytic activity | GO:0004064; arylesterase activity | 4.763E-05 | 6.564E-03 | CA1, CA2 |
| BP | GO:0040011; locomotion | GO:0030334; regulation of cell migration | 5.763E-05 | 7.794E-03 | CYP19A1, CYP1B1, HIF1A, LMNA, PPARD, PPARG, TERT, TP53 |
| MF | GO:0003824; catalytic activity | GO:0016616; oxidoreductase activity, acting on the CH-OH group of donors, NAD or NADP as acceptor | 6.186E-05 | 8.315E-03 | AKR1B1, CBR1, HPGD, HSD17B10 |
| BP | GO:0008152; metabolic process | GO:0009820; alkaloid metabolic process | 6.660E-05 | 8.736E-03 | CYP1A2, CYP3A4 |
| MF | GO:0005488; binding | GO:0097371; MDM2/MDM4 family protein binding | 6.660E-05 | 8.736E-03 | PPARA, TP53 |
| BP | GO:0023052; signaling | GO:0046887; positive regulation of hormone secretion | 7.492E-05 | 9.710E-03 | CYP19A1, FFAR1, HIF1A, PPARD |
Enriched KEGG Pathways of Target Proteins (Activity≤10μM)
Top 10, ordered by adjusted p-value
Detailed Information of Enriched KEGG Pathways
| Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|
| hsa00910 | Nitrogen metabolism_Homo sapiens_hsa00910 | 2.231E-13 | 1.852E-11 | CA12; CA1; CA2; CA4; CA7; CA9 |
| hsa05204 | Chemical carcinogenesis_Homo sapiens_hsa05204 | 9.191E-11 | 3.814E-09 | CYP2C9; CBR1; CYP1A2; CYP1A1; CYP1B1; CYP3A4; CYP2C19 |
| hsa00980 | Metabolism of xenobiotics by cytochrome P450_Homo sapiens_hsa00980 | 2.862E-09 | 5.938E-08 | CYP2C9; CBR1; CYP1A2; CYP1A1; CYP1B1; CYP3A4 |
| hsa00591 | Linoleic acid metabolism_Homo sapiens_hsa00591 | 1.404E-09 | 3.883E-08 | CYP2C9; CYP1A2; ALOX15; CYP3A4; CYP2C19 |
| hsa00140 | Steroid hormone biosynthesis_Homo sapiens_hsa00140 | 5.223E-08 | 8.670E-07 | CYP1A2; CYP1A1; CYP1B1; CYP3A4; CYP19A1 |
| hsa03320 | PPAR signaling pathway_Homo sapiens_hsa03320 | 1.263E-07 | 1.748E-06 | FABP3; FABP5; PPARG; PPARA; PPARD |
| hsa01100 | Metabolic pathways_Homo sapiens_hsa01100 | 5.169E-06 | 4.767E-05 | CYP2C9; CBR1; CYP1A2; ALOX15; CYP1A1; AKR1B1; CYP2C19; CYP3A4; CYP19A1; HSD17B10; XDH |
| hsa00590 | Arachidonic acid metabolism_Homo sapiens_hsa00590 | 4.078E-06 | 4.767E-05 | CYP2C9; CBR1; ALOX15; CYP2C19 |
| hsa00830 | Retinol metabolism_Homo sapiens_hsa00830 | 4.931E-06 | 4.767E-05 | CYP2C9; CYP1A2; CYP1A1; CYP3A4 |
| hsa00982 | Drug metabolism - cytochrome P450_Homo sapiens_hsa00982 | 6.266E-06 | 5.200E-05 | CYP2C9; CYP1A2; CYP3A4; CYP2C19 |
| hsa00380 | Tryptophan metabolism_Homo sapiens_hsa00380 | 4.640E-05 | 3.209E-04 | CYP1A2; CYP1A1; CYP1B1 |
| hsa04913 | Ovarian steroidogenesis_Homo sapiens_hsa04913 | 9.095E-05 | 5.807E-04 | CYP1A1; CYP1B1; CYP19A1 |
| hsa05200 | Pathways in cancer_Homo sapiens_hsa05200 | 5.973E-04 | 3.305E-03 | CDK6; PPARG; HIF1A; TP53; PPARD |
| hsa04976 | Bile secretion_Homo sapiens_hsa04976 | 2.586E-04 | 1.533E-03 | CA2; CYP3A4; ABCG2 |
| hsa04726 | Serotonergic synapse_Homo sapiens_hsa04726 | 9.820E-04 | 4.794E-03 | CYP2C9; ALOX15; CYP2C19 |
| hsa05202 | Transcriptional misregulation in cancer_Homo sapiens_hsa05202 | 3.797E-03 | 1.576E-02 | HPGD; PPARG; TP53 |
| hsa05223 | Non-small cell lung cancer_Homo sapiens_hsa05223 | 4.318E-03 | 1.707E-02 | CDK6; TP53 |
| hsa05214 | Glioma_Homo sapiens_hsa05214 | 5.775E-03 | 2.118E-02 | CDK6; TP53 |
| hsa05212 | Pancreatic cancer_Homo sapiens_hsa05212 | 5.949E-03 | 2.118E-02 | CDK6; TP53 |
| hsa00983 | Drug metabolism - other enzymes_Homo sapiens_hsa00983 | 2.934E-03 | 1.282E-02 | CYP3A4; XDH |
| hsa05230 | Central carbon metabolism in cancer_Homo sapiens_hsa05230 | 6.125E-03 | 2.118E-02 | TP53; HIF1A |
| hsa05218 | Melanoma_Homo sapiens_hsa05218 | 6.854E-03 | 2.188E-02 | CDK6; TP53 |
| hsa05216 | Thyroid cancer_Homo sapiens_hsa05216 | 1.173E-03 | 5.407E-03 | PPARG; TP53 |
| hsa05220 | Chronic myeloid leukemia_Homo sapiens_hsa05220 | 7.233E-03 | 2.223E-02 | CDK6; TP53 |
| hsa05206 | MicroRNAs in cancer_Homo sapiens_hsa05206 | 1.494E-02 | 4.134E-02 | CDK6; CYP1B1; TP53 |
| hsa04211 | Longevity regulating pathway - mammal_Homo sapiens_hsa04211 | 1.176E-02 | 3.365E-02 | PPARG; TP53 |
| hsa05222 | Small cell lung cancer_Homo sapiens_hsa05222 | 9.918E-03 | 2.940E-02 | CDK6; TP53 |
| hsa04115 | p53 signaling pathway_Homo sapiens_hsa04115 | 6.485E-03 | 2.153E-02 | CDK6; TP53 |
| hsa04919 | Thyroid hormone signaling pathway_Homo sapiens_hsa04919 | 1.809E-02 | 4.843E-02 | TP53; HIF1A |
| hsa04964 | Proximal tubule bicarbonate reclamation_Homo sapiens_hsa04964 | 7.355E-04 | 3.816E-03 | CA2; CA4 |
| hsa00232 | Caffeine metabolism_Homo sapiens_hsa00232 | 2.965E-05 | 2.237E-04 | CYP1A2; XDH |
Human Diseases Associated with the Target Proteins of the Plant (Activity≤10μM)
Detailed Information of Human Diseases
| ICD10 Disease Category | Disease Name | ICD10 Code | Linked Targets |
|---|---|---|---|
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Nicotine dependence | F17 | PPARG |
| I00-I99: Diseases of the circulatory system | Pulmonary arterial hypertension | I27.0, I27.2 | HIF1A |
| C00-D49: Neoplasms | Bladder cancer | C67 | CYP19A1 |
| N00-N99: Diseases of the genitourinary system | Prostate disease | N42.9 | CYP19A1 |
| C00-D49: Neoplasms | Brain cancer | C71, D33 | TERT |
| G00-G99: Diseases of the nervous system G00-G99 | Neurodegenerative disease | G30-G32 | MAPT |
| C00-D49: Neoplasms | Tumors | C00-D48 | TERT |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 1 diabetes | E10 | PPARD; PPARG |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Toxicity | T36-T50, T51-T65 | TP53 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 2 diabetes | E11 | FFAR1; PPARD; PPARG; PPARG |
| C00-D49: Neoplasms | Solid tumours | C00-D48 | HIF1A; TP53; CA9 |
| G00-G99: Diseases of the nervous system G00-G99 | Encephalopathy | G93.4 | XDH |
| NA: NA | Edema | NA | CA2 |
| I00-I99: Diseases of the circulatory system | Edema associated with congestive heart failure | I50, R60.9 | CA2 |
| N00-N99: Diseases of the genitourinary system | Endometriosis | N80 | CYP19A1; PPARG |
| A00-B99: Certain infectious and parasitic diseases | Bacterial infections | A00-B99 | CYP2C9 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Obesity | E66 | PPARD; PPARD; PPARG |
| K00-K95: Diseases of the digestive system | Non-alcoholic fatty liver disease | K76.0 | PPARD; PPARG |
| E00-E89: Endocrine, nutritional and metabolic diseases | Non-insulin dependent diabetes | E11.9 | FFAR1 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Insomnia | F51.0, G47.0 | CA2 |
| C00-D49: Neoplasms | Inflammatory disease | C11, C44, K75.9, M00-M25 | FAAH |
| K00-K95: Diseases of the digestive system | Inflammatory bowel disease | K50, K51 | PPARG |
| NA: NA | Dyslipidemia | NA | PPARD |
| E00-E89: Endocrine, nutritional and metabolic diseases | Dyslipidaemias | E78 | PPARD; PPARD |
| I00-I99: Diseases of the circulatory system | Atherosclerosis | I70 | PPARD |
| C00-D49: Neoplasms | Lymphoma | C81-C86 | HIF1A; CA9 |
| K00-K95: Diseases of the digestive system | Liver disease | K70-K77 | FAAH |
| K00-K95: Diseases of the digestive system | Duodenal ulcers | K25-K27 | CA2; CA1 |
| C00-D49: Neoplasms | Hematological malignancies | C81-C86 | TP53 |
| C00-D49: Neoplasms | Head and neck cancer | C07-C14, C32-C33 | TP53; AKR1B1; TERT |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Drug abuse | F10-F19 | PPARG |
| C00-D49: Neoplasms | Liver cancer | C22 | TERT |
| J00-J99: Diseases of the respiratory system | Asthma | J45 | CBR1 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Rheumatoid arthritis | M05-M06 | AKR1B1 |
| I00-I99: Diseases of the circulatory system | High blood pressure | I10-I16 | CA2 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic neuropathy | E11.40 | AKR1B1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic complication | E08-E13 | AKR1B1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic cataract | E10.36, E11.36 | AKR1B1 |
| C00-D49: Neoplasms | Ovarian cancer | C56 | TERT |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetes | E23.2, N25.1 | FFAR1; AKR1B1; PPARG |
| C00-D49: Neoplasms | Pancreatic cancer | C25 | TERT |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperlipidaemia | E78 | PPARD |
| H00-H59: Diseases of the eye and adnexa | Ocular inflammation | H16.229 | TERT; PPARG |
| H00-H59: Diseases of the eye and adnexa | Ocular hypertension | H40.0 | CA4; CA4 |
| H00-H59: Diseases of the eye and adnexa | Open-angle glaucoma | H40-H42 | CA2; CA4 |
| C00-D49: Neoplasms | Breast cancer | C50 | CYP19A1; CA9; TERT |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperuricaemia in gout | E79.0, M10 | XDH |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Gout | M10 | AKR1B1; XDH; PPARG |
| H00-H59: Diseases of the eye and adnexa | Glaucoma | H40-H42 | CA1; CA1; AKR1B1 |
| C00-D49: Neoplasms | Multiple myeloma | C90 | TERT |
| I00-I99: Diseases of the circulatory system | Heart failure | I50 | XDH |
| H60-H95: Diseases of the ear and mastoid process | Hearing disorder | H90.5 | TP53 |
| G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | MAPT; PPARG; PPARG |
| C00-D49: Neoplasms | Late-stage solid tumors | C00-C75, C7A, C7B, D10-D36, D3A | TP53 |
| C00-D49: Neoplasms | Oral cavity cancer | C00-C08 | TP53 |
| C00-D49: Neoplasms | Colorectal cancer | C18-C21 | TP53 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anxiety disorder | F32, F40-F42 | CYP3A4; FAAH |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Anesthesia | R20.0 | FAAH |
| C00-D49: Neoplasms | Hormonally-responsive breast cancer | C50 | CYP19A1 |
| C00-D49: Neoplasms | Renal cancer | C64 | CA9 |
| C00-D49: Neoplasms | Prostate cancer | C61 | TERT |
| C00-D49: Neoplasms | Acute myeloid leukemia | C92.0 | TP53; TP53; TERT |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperuricemia | E79.0 | XDH |
| C00-D49: Neoplasms | Cancer | C00-C96 | HIF1A; TP53; CA1; CA9 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Metabolic disorders | E70-E89 | PPARD |
| C00-D49: Neoplasms | Clear cell renal cell carcinoma | C64 | CA9 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cognitive disorders | F01-F07, F04, F05, R41.3 | MAPT |
| G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | FAAH |
| G00-G99: Diseases of the nervous system G00-G99 | Central nervous system disease | G00-G99 | PPARD; MAPT |
| H00-H59: Diseases of the eye and adnexa | Chronic glaucoma | H40-H42 | CA1 |
| C00-D49: Neoplasms | Advanced breast cancer | C50 | CYP19A1 |
| C00-D49: Neoplasms | Melanoma | C43 | TERT |
| I00-I99: Diseases of the circulatory system | Renal artery disease | I70.1 | TP53 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Major depressive disorder | F32, F33, M32 | FAAH |